FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Auffarth Gerd 2. Issuer Name and Ticker or Trading Symbol Outlook Therapeutics, Inc. [ OTLK ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)__X__ Director                    _____ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)         (First)         (Middle)
C/O OUTLOOK THERAPEUTICS, INC., 7 CLARKE DRIVE
3. Date of Earliest Transaction (MM/DD/YYYY)
4/20/2020
(Street)
CRANBURY, NJ 08512
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)  $0.72  4/20/2020    A     25000       (1) 4/20/2030  Common Stock  25000  $0.00  25000  D   

Explanation of Responses:
(1)  The option will vest in three equal annual installments such that the stock option will be fully vested as of the third anniversary of the grant date, subject to (x) the Reporting Person's Continuous Service to the Issuer through such vesting date and (y) acceleration upon a Change in Control.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Auffarth Gerd
C/O OUTLOOK THERAPEUTICS, INC.
7 CLARKE DRIVE
CRANBURY, NJ 08512
X



Signatures
/s/ Lawrence Kenyon, Attorney-in-Fact 4/21/2020
**Signature of Reporting Person Date
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Sep 2020 to Oct 2020 Click Here for more Outlook Therapeutics Charts.
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Oct 2019 to Oct 2020 Click Here for more Outlook Therapeutics Charts.